TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06754605: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (SCTV02) in Healthy Adults ≥18 Years of Age

Sponsor: Sinocelltech Ltd. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT06754605 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06754605 Rescue Dossier →